Trial Profile
An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Sep 2017 New trial record